Skip to main content
SpringerLink
Log in

CNS Complications of Breast Cancer

Current and Emerging Treatment Options

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

In general, the development of CNS metastases of breast cancer depends on several prognostic factors, including younger age and a negative hormone receptor status. Also, the presence of a breast cancer 1, early onset (BRCA1) germline mutation and expression of the human epidermal growth factor receptor 2 (Her2/ neu) proto-oncogene seem to contribute to an increased rate of development of CNS metastases.

The choice of appropriate therapy for brain metastases also depends on prognostic factors, including the age of the patient, the Karnofsky performance score, the number of brain metastases and the presence of systemic disease. Surgery followed by whole brain radiation therapy (WBRT) is generally restricted to ambulant patients with a single brain metastasis without active extracranial disease. In patients who have two to four metastases, stereotactic focal radiotherapy (i.e. radiosurgery) with or without WBRT is usually indicated. In the remainder of patients, WBRT alone provides adequate palliation. Although breast carcinoma is sensitive to chemotherapy, the role of chemotherapy in the treatment of brain metastases is still unclear. Objective responses after cyclophosphamide-based therapies were reported in studies performed in the 1980s. Subgroup analysis of data from a randomised study indicates that survival may improve if WBRT is combined with the radiosensitiser efaproxiral. Interestingly, the Her2/neu antibody trastuzumab, which does not cross the blood-brain barrier, produces systemic responses and enhanced survival, without a clear effect on brain metastases.

Breast cancer constitutes the most common solid primary tumour leading to leptomeningeal disease. Clinical symptoms such as cranial nerve dysfunction or a cauda equina syndrome can be treated with local radiotherapy. A randomised study in patients with leptomeningeal disease secondary to breast cancer has revealed that intrathecal chemotherapy is associated with substantially more adverse effects than non-intrathecal treatment, without a clear benefit in terms of response or survival.

Intramedullary metastasis is rare but often presents with a rapidly progressive myelopathy. Local radiotherapy may preserve neurological function.

Epidural spinal cord metastasis occurs in approximately 4% of patients and can lead to paraplegia. A randomised study has shown that surgical intervention together with local radiotherapy is superior to local radiotherapy alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin 2003 Feb; 21(1): 25–66

    Article  PubMed  Google Scholar 

  2. Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981 Jul 15; 48(2): 384–94

    Article  PubMed  CAS  Google Scholar 

  3. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993 Jun; 33(6): 583–90

    Article  PubMed  CAS  Google Scholar 

  4. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990 Feb 22; 322(8): 494–500

    Article  PubMed  CAS  Google Scholar 

  5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 2001 Mar 15; 344(11): 783–92

    Article  PubMed  CAS  Google Scholar 

  6. Lai R, Dang CT, Malkin MG, et al. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004 Aug 15; 101(4): 810–6

    Article  PubMed  CAS  Google Scholar 

  7. Rogers LR. Cerebrovascular complications of cancer. Neurol Clin 2003; 21(1): 167–92

    Article  PubMed  Google Scholar 

  8. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 May 23; 54(10): 1886–93

    CAS  Google Scholar 

  9. Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993 Sep; 43(9): 1678–83

    Article  PubMed  CAS  Google Scholar 

  10. Christiaans MH, Kelder JC, Arnoldus EP, et al. Prediction of intracranial metastases in cancer patients with headache. Cancer 2002 Apr 1; 94(7): 2063–8

    Article  PubMed  Google Scholar 

  11. Herman MA, Tremont-Lukats I, Meyers CA, et al. Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol 2003 Jun; 26(3): 273–9

    PubMed  Google Scholar 

  12. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003 Jul 1; 21(13): 2529–36

    Article  PubMed  CAS  Google Scholar 

  13. Regine WF, Scott C, Murray K, et al. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04. Int J Radiat Oncol Biol Phys 2001 Nov 1; 51(3): 711–7

    Article  PubMed  CAS  Google Scholar 

  14. Rivas E, Sanchez-Herrero J, Alonso M, et al. Miliary brain metastases presenting as rapidly progressive dementia. Neuropathology 2005 Jun; 25(2): 153–8

    Article  PubMed  Google Scholar 

  15. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004 Jul 15; 22(14): 2865–72

    Article  PubMed  Google Scholar 

  16. Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002 May 15; 94(10): 2698–705

    Article  PubMed  Google Scholar 

  17. Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983 Dec 15; 52(12): 2349–54

    CAS  Google Scholar 

  18. Slimane K, Andre F, Delaloge S, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004 Nov; 15(11): 1640–4

    Article  PubMed  CAS  Google Scholar 

  19. Albiges L, Andre F, Balleyguier C, et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol 2005 Nov; 16(11): 1846–7

    Article  PubMed  CAS  Google Scholar 

  20. Ryberg M, Nielsen D, Osterlind K, et al. Predictors of central nervous system metastasis in patients with metastatic breast cancer: a competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 2005 Jun; 91(3): 217–25

    Article  PubMed  Google Scholar 

  21. Evans AJ, James JJ, Cornford EJ, et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004 Aug; 16(5): 345–9

    Article  CAS  Google Scholar 

  22. Boogerd W, Vos VW, Hart AA, et al. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 1993 Feb; 15(2): 165–74

    Article  PubMed  CAS  Google Scholar 

  23. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of cerbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991 Nov 11; 49(5): 650–5

    Article  PubMed  CAS  Google Scholar 

  24. Marshall C, Blackburn E, Clark M, et al. Neuregulins 1–4 are expressed in the cytoplasm or nuclei of ductal carcinoma (in situ) of the human breast. Breast Cancer Res Treat 2006; 96(2): 163–8

    Article  PubMed  CAS  Google Scholar 

  25. Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003 Jul; 14(7): 1072–7

    Article  PubMed  CAS  Google Scholar 

  26. Myers RE, Johnston M, Pritchard K, et al. Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 2001 May 15; 164(10): 1439–44

    PubMed  CAS  Google Scholar 

  27. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999; 44(3): 275–81

    Article  PubMed  CAS  Google Scholar 

  28. Yuh WT, Tali ET, Nguyen HD, et al. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 1995 Feb; 16(2): 373–80

    PubMed  CAS  Google Scholar 

  29. Yuh WT, Fisher DJ, Runge VM, et al. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 1994 Jun; 15(6): 1037–51

    PubMed  CAS  Google Scholar 

  30. Van Dijk P, Sijens PE, Schmitz PI, et al. Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size. Magn Reson Imaging 1997; 15(5): 535–41

    Article  PubMed  Google Scholar 

  31. Bukte Y, Paksoy Y, Genc E, et al. Role of diffusion-weighted MR in differential diagnosis of intracranial cystic lesions. Clin Radiol 2005 Mar; 60(3): 375–83

    Article  PubMed  CAS  Google Scholar 

  32. Rees J. Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol 2003 Dec; 16(6): 643–50

    Article  PubMed  Google Scholar 

  33. Chiang IC, Kuo YT, Lu CY, et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004 Aug; 46(8): 619–27

    Article  PubMed  Google Scholar 

  34. Benard F, Turcotte E. Imaging in breast cancer: single-photon computed tomography and positron-emission tomography. Breast Cancer Res 2005; 7(4): 153–62

    Article  PubMed  CAS  Google Scholar 

  35. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005 Mar; 90(2): 105–12

    Article  PubMed  CAS  Google Scholar 

  36. Uematsu T, Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 2005 Apr; 184(4): 1266–73

    PubMed  Google Scholar 

  37. Abe K, Sasaki M, Kuwabara Y, et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005 Oct; 19(7): 573–9

    Article  PubMed  Google Scholar 

  38. Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16mg per day. Neurology 1994 Apr; 44(4): 675–80

    Article  PubMed  CAS  Google Scholar 

  39. Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004 Dec; 79(12): 1489–94

    Article  PubMed  Google Scholar 

  40. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003 Jul; 2(7): 404–9

    Article  PubMed  CAS  Google Scholar 

  41. Wagner GL, Wilms EB, Van Donselaar CA, et al. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 2003; 12(8): 585–6

    Article  PubMed  CAS  Google Scholar 

  42. Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med 1971 Feb; 111(2): 334–6

    PubMed  CAS  Google Scholar 

  43. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996 Oct 1; 78(7): 1470–6

    Article  PubMed  CAS  Google Scholar 

  44. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998 Nov 4; 280(17): 1485–9

    Article  PubMed  CAS  Google Scholar 

  45. Boyd TS, Mehta MP. Stereotactic radiosurgery for brain metastases. Oncology (Huntingt) 1999 Oct; 13(10): 1397–409

    CAS  Google Scholar 

  46. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004 May 22; 363(9422): 1665–72

    Article  PubMed  Google Scholar 

  47. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986 Aug 15; 58(4): 832–9

    Article  PubMed  CAS  Google Scholar 

  48. Boogerd W, Dalesio O, Bais EM, et al. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992 Feb 15; 69(4): 972–80

    Article  PubMed  CAS  Google Scholar 

  49. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999 Apr 1; 85(7): 1599–605

    Article  PubMed  CAS  Google Scholar 

  50. Cocconi G, Lottici R, Bisagni G, et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990; 8(3–4): 327–34

    Article  PubMed  CAS  Google Scholar 

  51. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000 Jul; 6(7): 2585–97

    PubMed  CAS  Google Scholar 

  52. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004 Jun 1; 10(11): 3728–36

    Article  PubMed  CAS  Google Scholar 

  53. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 Mar 10; 352(10): 987–96

    Article  PubMed  CAS  Google Scholar 

  54. Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001 Jul; 53(3): 259–65

    Article  PubMed  CAS  Google Scholar 

  55. Friedman HS, Evans B, Reardon D, et al. Phase II trial of temozolomide for patients with progressive brain metastases [abstract]. Proc Am Soc Clin Oncol 2003; 22: 102

    Article  Google Scholar 

  56. Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001 Feb; 12(2): 249–54

    Article  PubMed  CAS  Google Scholar 

  57. Trudeau ME, Crump M, Charpentier D, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada —Clinical Trials Group (NCIC-CTG). Ann Oncol 2006 Jun; 17(6): 952–6

    Article  PubMed  CAS  Google Scholar 

  58. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002 Sep 1; 20(17): 3644–50

    Article  PubMed  CAS  Google Scholar 

  59. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005 Jan 1; 61(1): 185–91

    Article  PubMed  CAS  Google Scholar 

  60. Christodoulou C, Bafaloukos D, Linardou H, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005 Jan; 71(1): 61–5

    Article  PubMed  CAS  Google Scholar 

  61. Omuro AMP, Raizer JJ, Abrey LE. A phase I trial of temozolomide and vinorelbine in patients with recurrent brain metastasis [abstract]. J Clin Oncol 2004; 22(14S): 1567

    Google Scholar 

  62. Caraglia M, Addeo R, Costanzo R, et al. Pegylated liposomal doxorubicin plus temozolomide in the salvage treatment of brain metastasis: the update [abstract]. J Clin Oncol 2004; 22(14S): 1576

    Google Scholar 

  63. Maki DD, Grossman RI. Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol 2000 Jun; 21(6): 1064–6

    PubMed  CAS  Google Scholar 

  64. Pors H, von Eyben FE, Sorensen OS, et al. Longterm remission of multiple brain metastases with tamoxifen. J Neurooncol 1991 Apr; 10(2): 173–7

    Article  PubMed  CAS  Google Scholar 

  65. van der Gaast A, Alexieva-Figusch J, Vecht C. Complete remission of a brain metastasis to third-line hormonal treatment with megestrol acetate. Am J Clin Oncol 1990 Dec; 13(6): 507–9

    Article  PubMed  Google Scholar 

  66. Stewart DJ, Dahrouge S. Response of brain metastases from breast cancer to megestrol acetate: a case report. J Neurooncol 1995; 24(3): 299–301

    Article  PubMed  CAS  Google Scholar 

  67. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991 Feb 20; 83(4): 288–91

    Article  PubMed  CAS  Google Scholar 

  68. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003 Feb 15; 21(4): 588–92

    Article  PubMed  Google Scholar 

  69. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999 Aug; 17(8): 2341–54

    PubMed  CAS  Google Scholar 

  70. Fellner S, Bauer B, Miller DS, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002 Nov; 110(9): 1309–18

    PubMed  CAS  Google Scholar 

  71. Freilich RJ, Seidman AD, DeAngelis LM. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 1995 Jul 15; 76(2): 232–6

    Article  PubMed  CAS  Google Scholar 

  72. Crivellari D, Pagani O, Veronesi A, et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001 Mar; 12(3): 353–6

    Article  PubMed  CAS  Google Scholar 

  73. Schwonzen M, Kurbacher CM, Mailmann P. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 2000 Oct; 11(9): 681–5

    Article  PubMed  CAS  Google Scholar 

  74. Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998 Oct 29; 17(17): 2235–49

    Article  PubMed  CAS  Google Scholar 

  75. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006 Feb 8; 232(2): 123–38

    Article  PubMed  CAS  Google Scholar 

  76. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000 Jun; 18(11): 2349–51

    PubMed  CAS  Google Scholar 

  77. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 Jan 9; 235(4785): 177–82

    Article  PubMed  CAS  Google Scholar 

  78. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 May 12; 244(4905): 707–12

    Article  PubMed  CAS  Google Scholar 

  79. Littlejohns P. Trastuzumab for early breast cancer: evolution or revolution? Lancet Oncol 2006 Jan; 7(1): 22–3

    Article  PubMed  Google Scholar 

  80. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003 Jun 15; 97(12): 2972–7

    Article  PubMed  Google Scholar 

  81. Lower EE, Drosick DR, Blau R, et al. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 2003 Jun; 4(2): 114–9

    Article  PubMed  CAS  Google Scholar 

  82. Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007 Jan; 18(1): 23–8

    Article  PubMed  CAS  Google Scholar 

  83. Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005 Mar; 20; 23(9): 2114–6

    Article  PubMed  Google Scholar 

  84. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001 Dec; 1(2): 85–94

    PubMed  CAS  Google Scholar 

  85. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006 Sep; 24(25): 4107–15

    CAS  Google Scholar 

  86. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005 Aug 10; 23(23): 5305–13

    Article  PubMed  CAS  Google Scholar 

  87. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006; 11(10): 1047–57

    Article  PubMed  CAS  Google Scholar 

  88. Komarnicky LT, Phillips TL, Martz K, et al. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 1991 Jan; 20(1): 53–8

    Article  PubMed  CAS  Google Scholar 

  89. Phillips TL, Scott CB, Leibel SA, et al. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 1995 Sep 30; 33(2): 339–48

    Article  PubMed  CAS  Google Scholar 

  90. Young SW, Sidhu MK, Qing F, et al. Preclinical evaluation of gadolinium (III) texaphyrin complex: a new paramagnetic contrast agent for magnetic resonance imaging. Invest Radiol 1994 Mar; 29(3): 330–8

    Article  PubMed  CAS  Google Scholar 

  91. Sneed PK. Efaproxiral: should we hold our breath? J Clin Oncol 2006 Jan 1; 24(1): 13–5

    Article  PubMed  CAS  Google Scholar 

  92. Hou H, Khan N, O’Hara JA, et al. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: in vivo EPR oximetry study. Int J Radiat Oncol Biol Phys 2005 Apr 1; 61(5): 1503–9

    Article  PubMed  CAS  Google Scholar 

  93. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006 Jan 1; 24(1): 106–14

    Article  PubMed  CAS  Google Scholar 

  94. Shaw E, Scott C, Suh J, et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol 2003 Jun 15; 21(12): 2364–71

    Article  PubMed  CAS  Google Scholar 

  95. Stea B, Suh J, Shaw E, et al. Efaproxiral (EFAPROXYN) as an adjunct to whole brain radiation therapy for the treatment of brain metastases originating from breast cancer: updated survival results of the randomized REACH (RT-009) study [poster]. Proceedings of the 27th Annual San Antonio Breast Cancer Symposium; 2004 Dec 8–11; San Antonio. San Antonio (TX): Cancer Therapy & Research Center, 2005: 4064

    Google Scholar 

  96. US National Institutes of Health. Standard whole brain radiation therapy with supplemental oxygen, with or without concurrent RSR13 (efaproxiral), in women with brain metastases from breast cancer [online]. Available from URL: http://clinicaltrials.gov/ct/show/NCT00083304?order=1 [Accessed 2007 May 29]

  97. Maraveyas A, Sgouros J, Upadhyay S, et al. Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study. Br J Cancer 2005 Mar 14; 92(5): 815–9

    Article  PubMed  CAS  Google Scholar 

  98. Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003; 8(5): 398–410

    Article  PubMed  Google Scholar 

  99. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 1983 Jul; 23(3): 175–80

    Article  PubMed  CAS  Google Scholar 

  100. Jayson GC, Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol 1996 Oct; 7(8): 773–86

    Article  PubMed  CAS  Google Scholar 

  101. DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest 2005; 23(2): 145–54

    Article  PubMed  Google Scholar 

  102. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982 Feb 15; 49(4): 759–72

    Article  PubMed  CAS  Google Scholar 

  103. Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995 Jun 15; 75(12): 2919–31

    Article  PubMed  CAS  Google Scholar 

  104. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975 Jul 24; 293(4): 161–6

    Article  PubMed  CAS  Google Scholar 

  105. Chamberlain MC, Kormanik P, Howell SB, et al. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 1995 Sep; 52(9): 912–7

    Article  PubMed  CAS  Google Scholar 

  106. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999 Nov; 5(11): 3394–402

    PubMed  CAS  Google Scholar 

  107. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993 Mar; 11(3): 561–9

    CAS  Google Scholar 

  108. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987 Oct; 5(10): 1655–62

    PubMed  CAS  Google Scholar 

  109. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004 Dec; 40(18): 2726–33

    Article  PubMed  CAS  Google Scholar 

  110. Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997 Nov; 87(5): 694–9

    Article  PubMed  CAS  Google Scholar 

  111. Costigan DA, Winkelman MD. Intramedullary spinal cord metastasis: a clinocopathological study of 13 cases. J Neurosurg 1985 Feb; 62(2): 227–33

    Article  PubMed  CAS  Google Scholar 

  112. Schiff D, O’Neill BP. Intramedullary spinal cord metastases: clinical features and treatment outcome. Neurology 1996 Oct; 47(4): 906–12

    Article  PubMed  CAS  Google Scholar 

  113. Mut M, Schiff D, Shaffrey ME. Metastasis to nervous system: spinal epidural and intramedullary metastases. J Neurooncol 2005 Oct; 75(1): 43–56

    Article  PubMed  Google Scholar 

  114. Dunne JW, Harper CG, Pamphlett R. Intramedullary spinal cord metastases: a clinical and pathological study of nine cases. Q J Med 1986 Nov; 61(235): 1003–20

    PubMed  CAS  Google Scholar 

  115. Winkelman MD, Adelstein DJ, Karlins NL. Intramedullary spinal cord metastasis: diagnostic and therapeutic considerations. Arch Neurol 1987 May; 44(5): 526–31

    Article  PubMed  CAS  Google Scholar 

  116. Gasser T, Sandalcioglu IE, Hamalawi BE, et al. Surgical treatment of intramedullary spinal cord metastases of systemic cancer: functional outcome and prognosis. J Neurooncol 2005 Jun; 73(2): 163–8

    Article  PubMed  CAS  Google Scholar 

  117. Kalayci M, Cagavi F, Gui S, et al. Intramedullary spinal cord metastases: diagnosis and treatment: an illustrated review. Acta Neurochir (Wien) 2004 Dec; 146(12): 1347–54

    Article  CAS  Google Scholar 

  118. Constantini S, Miller DC, Allen JC, et al. Radical excision of intramedullary spinal cord tumors: surgical morbidity and long-term follow-up evaluation in 164 children and young adults. J Neurosurg 2000 Oct; 93(2 Suppl.): 183–93

    PubMed  CAS  Google Scholar 

  119. Hill ME, Richards MA, Gregory WM, et al. Spinal cord compression in breast cancer: a review of 70 cases. Br J Cancer 1993 Nov; 68(5): 969–73

    Article  PubMed  CAS  Google Scholar 

  120. Fornasier VL, Horne JG. Metastases to the vertebral column. Cancer 1975 Aug; 36(2): 590–4

    Article  PubMed  CAS  Google Scholar 

  121. Kim RY, Spencer SA, Meredith RF, et al. Extradural spinal cord compression: analysis of factors determining functional prognosis—prospective study. Radiology 1990 Jul; 176(1): 279–82

    PubMed  CAS  Google Scholar 

  122. Kienstra GE, Terwee CB, Dekker FW, et al. Prediction of spinal epidural metastases. Arch Neurol 2000 May; 57(5): 690–5

    Article  PubMed  CAS  Google Scholar 

  123. Sorensen S, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30A(1): 22–7

    Article  PubMed  CAS  Google Scholar 

  124. Vecht CJ, Haaxma-Reiche H, van Putten WL, et al. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology 1989 Sep; 39(9): 1255–7

    Article  PubMed  CAS  Google Scholar 

  125. Maranzano E, Latini P, Beneventi S, et al. Radiotherapy without steroids in selected metastatic spinal cord compression patients: a phase II trial. Am J Clin Oncol 1996 Apr; 19(2): 179–83

    Article  PubMed  CAS  Google Scholar 

  126. Greenberg HS, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol 1980 Oct; 8(4): 361–6

    Article  PubMed  CAS  Google Scholar 

  127. Martenson Jr JA, Evans RG, Lie MR. Treatment outcome and complications in patients treated for malignant epidural spinal cord compression (SCC). J Neurooncol 1985; 3(1): 77–84

    Article  PubMed  Google Scholar 

  128. Gerszten PC, Burton SA, Welch WC, et al. Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer 2005 Nov 15; 104(10): 2244–54

    Article  PubMed  Google Scholar 

  129. Witham TF, Khavkin YA, Gallia GL, et al. Surgery insight: current management of epidural spinal cord compression from metastatic spine disease. Nat Clin Pract Neurol 2006 Feb; 2(2): 87–94

    Article  PubMed  Google Scholar 

  130. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005 Aug 20; 366(9486): 643-8

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Neurology, Medical Center Haaglanden, P.O. Box 432, 2501 CK, The Hague, The Netherlands

    Evert C. A. Kaal &  Charles J. Vecht

Authors
  1. Evert C. A. Kaal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles J. Vecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles J. Vecht.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaal, E.C.A., Vecht, C.J. CNS Complications of Breast Cancer. CNS Drugs 21, 559–579 (2007). https://doi.org/10.2165/00023210-200721070-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200721070-00003

Keywords

Search

Navigation